Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010767 | 0.92 | VDR (0.58) | VDR | |
| SCHEMBL9010884 | 0.88 | VDR (0.91) | VDR | |
| SCHEMBL14469841 | 0.85 | VDR (0.59) | VDR | |
| SCHEMBL14107850 | 0.85 | VDR (0.66) | VDR | |
| SCHEMBL9010530 | 0.84 | VDR (0.60) | VDR | |
| SCHEMBL9009951 | 0.83 | VDR (1.00) | VDR | |
| SCHEMBL5984365 | 0.83 | VDR (1.00) | VDR | |
| SCHEMBL5984149 | 0.83 | VDR (1.00) | VDR | |
| SCHEMBL14107851 | 0.82 | VDR (0.66) | VDR | |
| SCHEMBL818214 | 0.82 | VDR (0.51) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7531527-B2 | 2-Propylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070213546-A1 | 2-Propylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7241747-B2 | 2-propylidene-19-nor-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213546-A1 | 2-Propylidene-19-nor-vitamin D compounds | VDR, CD14, CYP24A1 | VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.